Form 4: Charles River Laboratories Director Steven Barg Boosts Stake with Equity Grants

Charles River Laboratories International, Inc. Director Steven Barg reported the acquisition of common stock and stock options through equity grants, including restricted stock units in lieu of director fees, as part of a pre-arranged Rule 10b5-1 plan.

Summary

• Steven Barg, a Director of Charles River Laboratories International, Inc. (CRL), acquired additional securities on June 2, 2025.
• He acquired 481 shares of common stock at a price of $135.04 per share, which were granted in lieu of director service fees for the term commencing May 20, 2025.
• He also acquired 946 unvested restricted stock units at a price of $135.04 per unit.
• Additionally, Mr. Barg was granted 2,082 stock options with an exercise price of $135.04 per share.
• The restricted stock units (totaling 1,427 shares) and stock options become exercisable or vest upon the earlier of June 2, 2026, or the business day prior to the company's next annual meeting of shareholders.
• Following these transactions, Mr. Barg directly beneficially owns 1,427 shares of common stock and 2,082 stock options.
• All reported transactions were made pursuant to a Rule 10b5-1 plan, indicating they were pre-scheduled.

Sentiment

Score: 7

Explanation: The filing indicates a director increasing their stake in the company through routine equity compensation, which is generally viewed positively as it aligns management interests with shareholders. There are no negative financial implications or red flags within this specific filing.

Positives

• Director Steven Barg increased his direct beneficial ownership in Charles River Laboratories, which generally aligns his interests more closely with those of shareholders.
• The acquisition of 481 shares in lieu of director service fees indicates a preference for equity compensation, signaling confidence in the company's long-term value.
• The transactions were conducted under a Rule 10b5-1 plan, which suggests pre-planned and transparent equity compensation arrangements.

Risks

• The value of the acquired common stock, restricted stock units, and stock options is subject to market fluctuations, meaning their value could decrease if the company's stock price declines.

Future Outlook

The vesting schedule for the newly acquired restricted stock units and stock options extends to at least June 2, 2026, or the company's next annual meeting, indicating a future alignment of the director's interests with long-term company performance and retention of key leadership.

Industry Context

This Form 4 filing reflects standard equity compensation practices for directors in the life sciences and pharmaceutical services industry, where aligning director incentives with shareholder value through stock grants and options is common. Charles River Laboratories operates in a sector that often uses such compensation structures to attract and retain experienced leadership and foster long-term commitment.

Comparison to Industry Standards

• The compensation structure, involving restricted stock units and stock options, is a common practice for director compensation across various industries, including the life sciences sector.
• Companies like LabCorp (LH) or IQVIA (IQV), which operate in similar or related segments of the life sciences industry, also utilize comparable equity-based incentives for their executives and directors to foster long-term commitment and align interests with company performance.
• The specific grant values and vesting schedules are typical for non-executive director compensation, reflecting a balance between immediate compensation and long-term retention, consistent with industry benchmarks.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive, as the director's increased equity ownership further aligns their financial interests with shareholder value.
• Employees: No direct impact mentioned in this filing.
• Customers/Suppliers/Creditors: No direct impact mentioned in this filing.

Next Steps

• Monitoring the vesting of the restricted stock units and exercisability of the stock options on or after June 2, 2026, or the company's next annual meeting.
• Future Form 4 filings will report any subsequent changes in Steven Barg's beneficial ownership.

Key Dates

Keywords

Charles River Laboratories, CRL, Steven Barg, Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, Rule 10b5-1